What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge [Globe and Mail, The (Toronto, Canada)]
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA)
Last kiniksa pharmaceuticals international, plc - class a ordinary shares earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: Globe and Mail, The
The director reported still holding 27,418 Class A ordinary shares after the transaction. All shares were disposed directly, with no indirect or entity-attributed participation; the transaction did not involve derivative securities. Michael R Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) , reported the sale of 6,625 shares of Common Stock in an open-market transaction on April 9, 2026, according to an SEC Form 4 filing Transaction summary Metric Value Shares sold (direct) Transaction value Post-transaction shares (direct) Transaction value based on SEC Form 4 reported price ($46.69). Key questions How does this sale impact the insider's direct ownership of Common Stock? This transaction reduced Megna's direct Class A ordinary share holdings from 6,625 shares to 27,418. Were any derivative securities or indirect holdings involved in this transaction? No derivative securities or indirect holdings were involved; all 6,
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares news events
Weekly update
A roundup of the hottest topics
KNSA
News
- What This $309K Kiniksa Insider Sale Might Signal Amid a 120% Stock Surge [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals International (KNSA) had its price target raised by Wedbush from $53.00 to $58.00. They now have an "outperform" rating on the stock.MarketBeat
- Kiniksa's Heart's Home Campaign Puts ARCALYST Growth Prospects In Focus [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent PericarditisGlobeNewswire
KNSA
Earnings
- 2/24/26 - Miss
KNSA
Sec Filings
- 4/16/26 - Form ARS
- 4/16/26 - Form DEFA14A
- 4/16/26 - Form DEF
- KNSA's page on the SEC website